Bone morphogenetic protein 9 (BMP9)

Class

Anti-BMP9 monoclonal antibody (recombinant human IgG1)

Bone morphogenetic protein 9 (BMP9) is a circulating growth factor belonging to the transforming growth factor-beta (TGF-β) superfamily. It signals mainly through a receptor complex on blood vessel lining cells (endothelium) composed of the receptor ALK1 and the co-receptor endoglin, activating an intracellular cascade that shapes how blood vessels form, mature, and remain stable. This axis also influences bone-forming cells and tissue fibrosis. Because BMP9 signaling helps set the tone of vascular and connective tissue biology, its dysregulation has been implicated in diseases marked by abnormal blood vessel remodeling, excessive fibrous tissue deposition, or unwanted bone formation in soft tissue. An antibody designed to bind and neutralize BMP9 aims to reduce ligand availability before it can engage its receptor complex, thereby dampening downstream signaling in tissues where it has become pathologically overactive. This strategy is of interest in vascular diseases where the ALK1/endoglin pathway is disturbed, as well as in conditions involving pathological tissue calcification or fibrotic remodeling. As a large protein-based biologic, such an antibody acts extracellularly, distinguishing it from small-molecule kinase inhibitors that might instead block the receptor itself. Its therapeutic promise rests on selectively removing one ligand from a pathway with multiple biological roles, which requires balancing efficacy against the normal, physiological functions BMP9 performs in vascular and skeletal maintenance.